Criticare Systems Announces Immtech International IPO.MILWAUKEE--(BUSINESS WIRE)--May 3, 1999-- CRITICARE SYSTEMS, INC inc - /ink/ increment, i.e. increase by one. Especially used by assembly programmers, as many assembly languages have an "inc" mnemonic. Antonym: dec. . (NASDAQ-NMS:CXIM) announced today that Immtech International, in which Criticare holds a minority interest, is now publicly trading under the symbol IMMT IMMT International Maritime Meteorological Tape (WMO) IMMT Integrated Maintenance Management Team IMMT International Space Station Mission Management Team IMMT Identity Management Middle Tiers . Emil Soika, Criticare CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. , stated, "We are excited for both companies and their respective shareholders. Immtech stock became public on April 27, 1999 at $10 per share and closed at $26-1/4 on April 30. Criticare owns approximately one million shares and has conservatively carried the value of Immtech at zero on its balance sheet." Criticare Systems, Inc., designs, manufactures and markets cost-effective patient monitoring systems and noninvasive non·in·va·sive adj. 1. Not penetrating the body, as by incision. Used especially of a diagnostic procedure. 2. Not invading healthy tissue. sensors for a wide range of hospitals and alternate health care environments throughout the world. This press release contains forward-looking statements forward-looking statement A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections. . Such statements refer to the company's beliefs and expectations. Forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those described. Such uncertainties include, but are not limited to, the timely completion of new products, the risk of new and better technologies, as well as general conditions in the company's markets. It should be noted that there is risk in the investment of a biotechnology company concerning the demonstration of clinical effectiveness and time to market. |
|
||||||||||||||||

Printer friendly
Cite/link
Email
Feedback
Reader Opinion